First-Line Treatment of EGFR-mutated Nonsmall Cell Lung Cancer: Critical Review on Study Methodology

European Respiratory Review - United Kingdom
doi 10.1183/09059180.00008413
Full Text
Abstract

Available in full text

Date
Authors
Publisher

European Respiratory Society (ERS)

Related search

Refining the Treatment of Advanced Nonsmall Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2010English

P2.03-34 the Relationship Between Treatment Response and Serum EGFR Level in Nonsmall Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pcn44 - First-Line Treatment Efficacy in Egfr-Positive Non-Small Cell Lung Cancer: A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P1.15-19 Treatment of Choice for First-Line Therapy of EGFR-Mutated Stage IIIB Lung Adenocarcinoma Based on the Real World Data

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Thyroid Metastasis From Nonsmall Cell Lung Cancer

Case Reports in Oncological Medicine
Oncology
2013English

TP53 Mutations in Nonsmall Cell Lung Cancer

Journal of Biomedicine and Biotechnology
2011English

Comparing the Efficacy of Concurrent EGFR-TKI and Whole-Brain Radiotherapy vs EGFR-TKI Alone as a First-Line Therapy for Advanced EGFR-mutated Non-Small-Cell Lung Cancer With Brain Metastases: A Retrospective Cohort Study

Cancer Management and Research
Oncology
2019English

Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Inactivation ofLLC1 Gene in Nonsmall Cell Lung Cancer

International Journal of Cancer
Cancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy